From Academic Scientist to Biotech Executive: Dr. Vishwas Seshadri Inspires ABI Participants with His Career Story
September 10, 2025
The Fall 2025 Accelerating BioVenture Innovation (ABI) course officially kicked off on Sept. 2 in Uris Auditorium with guest speaker Dr. Vishwas Seshadri, chief executive officer of Abeona Therapeutics, Inc. In a wide-ranging interview with BioVenture eLab Director Loren Busby, Dr. Seshadri, a scientist turned biotech executive, spoke about R&D, manufacturing, leadership, regulatory affairs and market access.
NIH Grant Funds Effort to Target the Root of HIV Persistence
August 15, 2025
A multi-institutional team led by Weill Cornell Medicine has received a five-year, $14.9 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to find ways to remove latent HIV from the cells of individuals with HIV. The team aims to use a personalized medicine approach to transform the management of HIV into effective cures.
Pitch Competition Showcases How Artificial Intelligence, Big Data May Benefit Patients
July 10, 2025
BioVenture eLab’s Biomedical Innovation Challenge program celebrated its seventh cohort on June 24 with a final pitch event and scientific presentations in Uris Auditorium. This year’s competitors showcased artificial intelligence-enabled solutions aimed at improving early disease detection and enhancing health outcomes at scale.
New Insights into Bladder Cancer Treatment Could Help Improve Immunotherapies
May 29, 2025
A team of researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center (MSK) is expanding the understanding of how Bacillus Calmette-Guérin (BCG) works as a treatment of bladder cancer— an understanding that could help improve the effectiveness of immunotherapies more broadly.
Expanded Funding Program Strengthens Enterprise Innovation’s Ability to Nurture Promising Early-Stage Research
May 21, 2025
To support the continued diversification of Weill Cornell Medicine’s technology portfolio, Enterprise Innovation has created an overarching gap funding superstructure to advance innovation and commercialization opportunities.Making a Real-World Impact with Tangible Research Materials Commercialization
May 16, 2025
Tangible materials developed by Weill Cornell Medicine investigators are valuable assets to both the research community and biomedical industry. By commercializing such materials, investigators can propel translational science as well as create revenue for their labs. Dr. Lukas Dow, a professor of biochemistry in medicine who has a decade of experience in commercializing tangible materials, shared his insights with Enterprise Innovation.
AI Tool Accurately Sorts Cancer Patients by their Likely Outcomes
May 12, 2025
A new artificial intelligence-based method accurately sorts cancer patients into groups that have similar characteristics before treatment and similar outcomes after treatment, according to a study led by investigators at Weill Cornell Medicine. The new approach has the potential to enable better patient selection in clinical trials and better treatment selection for individual patients.
The Power of Partnership in Innovation
April 14, 2025
Nearly 200 scientists, investors and industry representatives attended Weill Cornell Medicine’s 2025 Biomedical Innovation Conference (“BioInnovate”) April 1, sharing their startup journeys and experiences nurturing biomedical advances into health care products and companies.
New Strategy May Enable Cancer Monitoring from Blood Tests Alone
April 11, 2025
A new, error-corrected method for detecting cancer from blood samples is much more sensitive and accurate than prior methods and may be useful for monitoring disease status in patients following treatment, according to a study by Weill Cornell Medicine and New York Genome Center investigators. The method, based on whole-genome sequencing of DNA, also represents an important step toward the goal of routine blood test-based screening for early cancer detection.
